ClinicalTrials.gg
RecruitingNCT07635576Updated Oct 1, 2026

Effect of Gastric Electrical Stimulation on Serum Insulin Levels

An interventional study of Gastric Electrical Stimulator in Gastroparesis Nondiabetic, sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Indiana University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 1, 2026Eligibility revisedPrimary outcomes revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Gastroparesis by Indiana University — 7 open to participants now, 8 under way, none of them phase 3. Gastroparesis · Indiana University.

Started
2026
the only one that year
No phase
7 of 15
3 open now
Registered
14th of 15
by date

Among the 15 studies in Gastroparesis by Indiana University, this one is the only one that started in 2026, is one of 7 with no phase, and was the 14th registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

7 of the 15 studies in Gastroparesis by Indiana University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Gastroparesis by Indiana University, or all of them as a file.
02

Study summary

The goal of this study is to determine how much effect turning off an individual's Gastric Electrical Stimulator (GES) for up to four hours will have on levels of insulin, C-peptide, GLP-1 and glucose levels.

Read the detailed description

Up to thirty-two adult patients with gastroparesis who have undergone implantation of a gastric stimulation device at least three months prior may participate in this study, which will be completed at a single study visit.

The study consists of two groups, an EXPERIMENTAL group that undergoes turning off the GES and a CONTROL group that does not undergo the turning off of the GES. The subjects are randomized to either the control or experimental group.

After an overnight fast, consented and eligible patients are placed in the supine position on a hospital bed, and an intravenous line is inserted and capped. EKG electrodes will be placed on the chest, arms/legs, behind each ear and just under the jaw on each side to record cardiac and vagal nerve activity.

The study consists of three separate and consecutive periods:

  1. Baseline, a 20-minute period during which GES is left ON at each patient's pre-study settings;
  2. Experimental, a 4-hour period during which the GES device is turned OFF for participants in the experimental group;
  3. Recovery, a 20-minute period during which GES is turned back ON to the patient's pre-study settings for participants in the experimental group.

A 5-ml sample of blood will be collected from each patient after placement of the flexible IV catheter secured with tape, and after the Baseline, and Recovery study periods. During the Experimental period a blood sample is withdrawn after 30 minutes and then again at the 1-hour, 2-hour, 3-hour and 4-hour intervals through a flexible IV catheter secured with tape, with the possibility of up to 8 blood draws over the duration of the study. EKG and vagal nerve activity will be recorded continuously through the 3 study periods.

03

Conditions studied

  • Gastroparesis Nondiabetic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age.
  • Documented diagnosis of gastroparesis
  • Not taking diabetic prescribed exogenous insulin.
  • Patient has a GES device that has been implanted for at least 3 months.
  • Willing to give up to 8 blood samples.
  • Willing to lie in a bed for up to 5.5 hours.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • History of allergic reaction to lead placement adhesives.
  • Unable to give .
  • Unwilling to give up to 8 5 ml blood samples.
  • Unwilling to lie in a bed for up to 5.5 hours.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    The OFF Group

    This group of subjects will have their GES interrogated and observed as well as having the device turned off for the duration of the experiment. The device will then be re-interrogated and turned back on at the end of the experiment.

    Device: Gastric Electrical Stimulator

  • No intervention
    Control Group

    This group of subjects will undergo the same procedures as the experimental group, except that their GES will not be turned off during the experimental period.

Interventions

  • DeviceGastric Electrical Stimulator

    Device will either be turned off for the duration of the experimental period.

    Also known as: GES

06

What researchers measure

Primary outcomes

  1. Change in serum insulin

    To define the effect of prolonged four-hour withdrawal of gastric electrical stimulation on serum insulin.

    Time frame: Day 1

  2. Change in serum C-peptide

    To define the effect of prolonged four-hour withdrawal of gastric in human subjects. Insulin and C-peptide are co-primary end points.

    Time frame: Day 1

Secondary outcomes

  1. Changes in serum glucose

    To compare the changes in serum GLP-1 and glucose levels after 4-hour withdrawal of gastric electrical stimulation to a control group that does not undergo withdrawal of gastric electrical stimulation.

    Time frame: Day 1

  2. Changes in serum GLP-1

    To compare the changes in serum GLP-1 and glucose levels after 4-hour withdrawal of gastric electrical stimulation to a control group that does not undergo withdrawal of gastric electrical stimulation.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Payne SC, Ward G, Fallon JB, Hyakumura T, Prins JB, Andrikopoulos S, MacIsaac RJ, Villalobos J. Blood glucose modulation and safety of efferent vagus nerve stimulation in a type 2 diabetic rat model. Physiol Rep. 2022 Apr;10(8):e15257. doi: 10.14814/phy2.15257. PubMed 35439355 ↗
  • Kozorosky EM, Lee CH, Lee JG, Nunez Martinez V, Padayachee LE, Stauss HM. Transcutaneous auricular vagus nerve stimulation augments postprandial inhibition of ghrelin. Physiol Rep. 2022 Apr;10(8):e15253. doi: 10.14814/phy2.15253. PubMed 35441808 ↗
  • Vosseler A, Zhao D, Fritsche L, Lehmann R, Kantartzis K, Small DM, Peter A, Haring HU, Birkenfeld AL, Fritsche A, Wagner R, Preissl H, Kullmann S, Heni M. No modulation of postprandial metabolism by transcutaneous auricular vagus nerve stimulation: a cross-over study in 15 healthy men. Sci Rep. 2020 Nov 24;10(1):20466. doi: 10.1038/s41598-020-77430-2. PubMed 33235256 ↗
  • van der Voort IR, Becker JC, Dietl KH, Konturek JW, Domschke W, Pohle T. Gastric electrical stimulation results in improved metabolic control in diabetic patients suffering from gastroparesis. Exp Clin Endocrinol Diabetes. 2005 Jan;113(1):38-42. doi: 10.1055/s-2004-830525. PubMed 15662594 ↗
  • Hampton RF, Jimenez-Gonzalez M, Stanley SA. Unravelling innervation of pancreatic islets. Diabetologia. 2022 Jul;65(7):1069-1084. doi: 10.1007/s00125-022-05691-9. Epub 2022 Mar 29. PubMed 35348820 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 56 non-industry interventional studies with no phase under Gastroparesis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 59. This study's planned 24 months is below that.

Counting every sponsor, half of 65 studies reached it within 28 months; a quarter within 11 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 9, 2026
StartActual
Jul 23, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Indiana University Hospital · Indianapolis, United States
Oct 1, 2026
Eligibility
Maximum age 70 Years→none
Oct 1, 2026
Interventions
Arms added: Control Group; arms removed: SHAM Group
Oct 1, 2026
Primary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedChange in serum insulinTime frame: Day 1
  • AddedChange in serum C-peptideTime frame: Day 1
  • RemovedDefinition of EffectTime frame: Day 1
Oct 1, 2026
Secondary outcomes
1 edited, 1 added, 3 removed
What changed in the outcomes
  • EditedChanges in Glucose and GLP-1 Levelsserum glucoseTime frame: Day 1
  • AddedChanges in serum GLP-1Time frame: Day 1
  • RemovedComparing Hormone LevelsTime frame: Day 1
  • RemovedDefinition of 4-Hour Withdrawl of GES DeviceTime frame: Day 1
  • Removedother outcomeTertiary ObjectiveTime frame: Day 1
Oct 1, 2026
Contact
Study contact changed: m•••@iu.edu · •••2064→m•••@iu.edu · •••2064. See the current contact
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    1 site removed
    Show 1 removed
    • Indiana University Hospital · Indianapolis, United States
    Eligibility Maximum age 70 Years→none
    Primary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedChange in serum insulinTime frame: Day 1
    • AddedChange in serum C-peptideTime frame: Day 1
    • RemovedDefinition of EffectTime frame: Day 1
    Secondary outcomes 1 edited, 1 added, 3 removed
    What changed in the outcomes
    • EditedChanges in Glucose and GLP-1 Levelsserum glucoseTime frame: Day 1
    • AddedChanges in serum GLP-1Time frame: Day 1
    • RemovedComparing Hormone LevelsTime frame: Day 1
    • RemovedDefinition of 4-Hour Withdrawl of GES DeviceTime frame: Day 1
    • Removedother outcomeTertiary ObjectiveTime frame: Day 1
    Interventions Arms added: Control Group; arms removed: SHAM Group
    Contact Study contact changed: m•••@iu.edu · •••2064→m•••@iu.edu · •••2064. See the current contact
    + 4 other changes: verification date, oversight details, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07635576
Lead sponsor
Indiana University
Responsible party
Thomas V. Nowak (Professor of Clinical Medicine, Indiana University) — Principal investigator
First posted
Jun 9, 2026
Start date
Jul 23, 2026
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Maureen V Schilling, BS
Contact
maschi@iu.edu
3172782064
Thomas V Nowak, MD
Contact
tvnowak@iu.edu
3179484272
Thomas V Nowak, MD
principal investigator · IU School of Medicine/IU Health

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion